Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

r parts of the body, has an especially poor prognosis, with a five-year survival rate of 27 percent. Currently, there are two and a half million breast cancer survivors in the United States. According to the ACS, breast cancer death rates are going down; the decline may be the result of early detection and treatment.

About the Study

Prior to study initiation, the Norton-Simon mathematical model (Norton et al, AACR 2005) -- which explores how the growth characteristics of a cancer affect response to chemotherapy -- was applied to determine that the maximum impact of Xeloda treatment in breast cancer patients occurs after seven days. Based on this finding, the single-center, open-label phase I/II trial was designed to determine the maximum tolerated dose (MTD) of Xeloda administered orally for seven days, followed by a seven-day rest (7-on/7-off), in patients with advanced-stage breast cancer. MTD was defined as the highest dose for which the incidence of dose-limiting toxicity (DLT) is less than 33 percent. DLT was defined as grade 3/4 hematologic toxicity lasting greater than two weeks despite growth factor support, or any grade 3/4 nonhematologic toxicity.

The Phase I study dose escalation scheme was a standard "3+3" design, using flat dosing that begins at 1,500 mg twice daily and increases by 500 mg/dose level until the MTD is reached. All patients in a cohort were observed for 28 days before enrollment to the next level is permitted to monitor for delayed toxicity.

The study showed that the dose dense regimen was well-tolerated in patients with advanced breast cancer, allowing safe delivery of higher daily doses than routinely used in practice. Of the 21 patients recruited for the trial, 18 were treated with Xeloda and reached a maximum tolerated dose of 2,000 mg twice daily. There were no grade 4/5 toxicities and grade 3 toxicities (which included one dose-limiting incident of hand-foot syndrome at 2,000 mg twice daily and two at 2,0
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications ... months ended June 30, 2015. "Our ... growth, as revenues increased 47 percent year-over-year and ... Officer Michael Davin. "While our international results reflected ...
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... July 28, 2015 ANI Pharmaceuticals, Inc. (NASDAQ: ... to release its second quarter and year-to-date 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
Breaking Medicine Technology:Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2
... Thousands of jobs in Texas supported by the ... – such as imposing new taxes in the Medicare ... From research to technical work, manufacturing to ... care services, the biopharmaceutical sector supports a broad array ...
... REDWOOD CITY, Calif. and SAO PAULO, Sept. 27, 2011 ... Raizen Energia S.A. today announced the signing of a ... ethanol process with enhanced performance economics. Raizen is Brazil,s ... the terms of the agreement, Raizen and Codexis will ...
Cached Medicine Technology:Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) ... from time to time and depending on market conditions, to repurchase shares of ... Repurchases will be made in open market or privately negotiated transactions in compliance ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... GA (PRWEB) , ... July 28, 2015 , ... ... been chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual ... row by hundreds of her esteemed colleagues and peers in the metro area as ...
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... Irvine, CA (PRWEB) , ... July 28, 2015 ... ... risk of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of ... clinical cardiology is the identification of individuals with active yet undetected sub-clinical disease, ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
... a statement of Matthew L. Myers, President, Campaign ... ) The Campaign for Tobacco-Free Kids applauds ... role in Senate committee approval of legislation that ... regulatory authority over tobacco products, including the authority ...
... of Clinical Oncology. , ... Evanston, IL (Vocus) May 20, 2009 -- ... David J. Winchester , FACS, M.D., Chief of General Surgery and Surgical ... cancer has spread to the lymph nodes may not need a ...
... Alan B. Miller to Retain Chairman and CEO Positions Michael ... Pa., May 20 The Board of Directors of Universal ... nation,s largest hospital companies, today announced the election of Marc ... of Universal Health Service,s Chairman and Chief Executive, Alan Miller, ...
... On May 20, 2009, the US District Court for the ... AZN ) for an injunction barring Apotex (Apotex, ... AstraZeneca,s PULMICORT RESPULES (budesonide inhalation suspension) in the US. ... March 30, 2009, the US Food and Drug Administration granted ...
... SCHAUMBURG, Ill., May 20 Sagent Pharmaceuticals, Inc., ... it has raised $30 million in a second ... strategic investors. The round was again led by ... support upcoming product launches, development activities and strategic ...
Cached Medicine News:Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:Breast Cancer Patients May be Spared Additional Surgery 2Health News:Breast Cancer Patients May be Spared Additional Surgery 3Health News:Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services 2Health News:Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation 2
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
Medicine Products: